Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 945-730-9
CAS number: -
Satellite females, five per group, were similarly treated and killed on
Day 16 of gestation, for determination of haematology and blood
Post-dose salivation was observed on a regular basis at 300 and 900
mg/kg/day in a doseage-related manner. Other signs observed at 900
mg/kg/day included brown staining, hailoss, urogenital staining,
piloerection and ungroomed coat. The general condition of females
receiving 100 and 300 mg/kg/day was similar to that of the Controls. No
Bodyweight stasis or loss was observed over Days 7 to 10 of gestation at
900 mg/kg/day, although the deficit was recouped by Day 20 of gestation.
Weight gains at 100 and 300 mg/kg/day were unaffected by treatment.
Food consumption was reduced at 900 mg/kg/day for the first few days of
the treatment period. Food consumption at 100 and 300 mg/kg/day was
similar to that of the Controls.
Water consumption showed a marked increase throughout the treatment
period, and up to termination, for females receiving 300 and 900
mg/kg/day. Water consumption at 100 mg/kg/day was unaffected by
With the exception of four females exhibiting hairloss at 900 mg/kg/day,
necropsy of females on Day 20 of gestation, revealed no macroscopic
findings that were considered to be an effect of treatment.
Litter survival, growth and development in utero was unaffected by
treatment with Diphenyl cresyl phosphate at all dosages.
On day 16 of gestation, packed cell volume, haemoglobin concentration
and red blood cell count were lower for all treated groups, although
females receiving 100 mg/kg bw were only marginally affected. Increased
total leucocyte counts, neutrophil and platelet counts were recorded at
300 and 900 mg/kg/day. Polychromasia and/ or hypochromasia were observed
for all females at 900 mg/kg/day.
Blood chemistry of females receiving 300 and 900 mg/kg/day revealed low
albumin concentrations, slightly high alpha-globulin and high
beta-globulin concentrations, and a lower albumin to globulin ratio. At
900 mg/kg/day, there were high alanine and aspartate amino-transferase
activities, and marginally low plasma glucose concentrations.
Females receiving 100 mg/kg/day were considered to be unaffected by
The influence of Diphenyl cresyl phosphate upon the progress and outcome
of pregnancy was assessed in sexually mature rats of the CD strain in
accordance with the guidelines of the OECD 414. For this purpose ,
Diphenyl cresyl phosphate was administered by gavage at dosages of 100,
300 or 900 mg/kg/day to groups of 22 pregnant rats from Day 6 to 15 of
gestation inclusive. Control animals received the vehicle, maize oil,
throughout the same period. All females were killed on Day 20 of
gestation for examination of their uterine contents.
It was concluded from this investigation that oral administration of
Diphenyl Cresyl phosphate to pregnant rats during the period of
organogenesis at a dosage of 900 mg/kg/day resulted in several findings
indicative of toxicity. These included reduced weight gain, increased
water consumption and an effect on erythrocytic parameters. The liver
was identified as a possible target organ.
At a dosage of 300 mg/kg/day, water consumption was increased, and
erythrocytic parameters were affected as for the highest dosage, but to
a lesser degree.
At the lowest dosage of 100 mg/kg/day, Diphenyl cresyl phosphate was
well tolerated with no signs of overt toxicity, and this was considered
to be the maternal NOAEL.
Litter parameters were unaffected by treatment at all dosages, and the
NOEL for foetuses was therefore considered to be 900 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again